Skip to main content
InnoCare Pharma Limited logo

InnoCare Pharma Limited — Investor Relations & Filings

Ticker · 9969 ISIN · KYG4783B1032 LEI · 3003001NYJPPWIEOJT79 HKEX Manufacturing
Open in API
Filings indexed 428 across all filing types
Latest filing 2025-08-20 Share Issue/Capital Cha…
Country KY Cayman Islands
Listing HKEX 9969

About InnoCare Pharma Limited

http://www.innocarepharma.com

InnoCare Pharma Limited is a commercial stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative drugs. The company focuses primarily on creating potentially best-in-class and first-in-class therapies for the treatment of cancer (oncology) and autoimmune diseases. InnoCare researches, develops, and commercializes its pipeline with the goal of delivering safe and effective treatments to patients globally.

Recent filings

Filing Released Lang Actions
GRANT OF RESTRICTED SHARES PURSUANT TO 2024 RMB SHARE INCENTIVE SCHEME
Share Issue/Capital Change Classification · 1% confidence The document is an announcement on the Hong Kong Stock Exchange regarding the grant of restricted shares under the Company’s 2024 RMB Share Incentive Scheme, detailing the date of grant, number of shares issued, vesting conditions, performance targets, and other scheme mechanics. It is not a general report (e.g., annual, interim, audit) nor a voting or delisting notice. Instead, it specifically relates to the issuance of new shares under an employee incentive plan, which falls under share issue/capital change disclosures. Therefore, the correct classification is SHA (Share Issue/Capital Change).
2025-08-20 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 1% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2025-08-19 English
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2025
Interim / Quarterly Report Classification · 1% confidence The document is an 'Interim Results Announcement' for InnoCare Pharma Limited for the six months ended 30 June 2025. It contains detailed financial highlights, consolidated financial data (revenue, expenses, loss), and a comprehensive management discussion of business operations and pipeline milestones. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H2 2025
2025-08-19 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 1% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2025-08-11 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2025
Regulatory Filings Classification · 1% confidence The document is a statutory HKEX FF301 Monthly Return showing movements in authorised share capital, issued and treasury shares, and related share schemes for the month ending 31 July 2025. It is not an Annual Report, earnings release, board change notice, nor a one-off share issuance or buyback announcement. Instead, it is a routine regulatory submission to the exchange under Listing Rule Chapter 19B. Therefore it falls under the general “Regulatory Filings” category (RNS), which serves as the fallback for miscellaneous regulatory forms and filings.
2025-08-05 English
DATE OF BOARD MEETING
Report Publication Announcement Classification · 1% confidence The document is a brief announcement from InnoCare Pharma Limited notifying shareholders of the date of an upcoming Board meeting to consider and approve the interim results for the six months ended June 30, 2025, and its publication. It does not contain the results themselves but simply the timing of a report’s approval and release. This matches the definition of a Report Publication Announcement (Code: RPA) under our classification guidelines.
2025-08-05 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.